Single Use Trocar Site Closure Device A fascial closure device is a laparoscopic instrument used to close the fascia, the layer of tissue that covers and separates abdominal organs and muscles. The device is used during laparoscopic surgery to create a secure closure of the fascia after the surgical procedure is complete.
The use of fascial closure devices during laparoscopic surgery can help reduce the risk of postoperative complications such as hernias, wound infections, and intestinal obstruction. It also closes the fascia more quickly and efficiently, reducing the overall time required for the procedure.
Single Use Trocar Site Closure Device,Medical Use Fascial Closure System,Single Use Fascial Closure System,Exit Fascia Closure Device Changzhou Weipu Medical Devices Co., Ltd. , https://www.cnweipumedical.com
The fascial closure device consists of a needle and suture material attached to a handle. A needle is used to puncture the fascia, then suture material is passed through the puncture site and tied tightly to close the fascia. The device's handle is used to control the movement of the needle and suture material, allowing precise placement and closure of the fascia.
New stem cell therapy is expected to completely cure leukemia
On December 5, the stem cell transplantation can effectively treat leukemia. However, in many cases, immune cells from donors attack the healthy tissues of the recipient's body, resulting in fatal consequences. Recently, one was published. In the research report of the international magazine Science Translational Medicine, scientists from institutions such as the University of Zurich identified a special molecule that plays a key role in the process. Blocking the function of the molecule can significantly improve the acceptance of stem cell transplantation. The prognosis of patients who are treated.
Stem cell therapy can bring hope to the complete recovery of patients with leukemia or bone marrow cancer, which requires removal of cells affected by chemotherapy or radiotherapy, followed by replacement of these cells with blood stem cells from healthy donor organisms. It can produce new blood cells and attack cancerous cells in the body of the patient, thereby inhibiting the recurrence of cancer.
Dangerous reaction
However, this therapy is not without risk. In 30%-60% of cases, cells from donors often attack healthy tissues of the recipient's body, especially liver, intestinal tissue and skin tissue; Affected patients, such as graft-versus-host reactions, can even have fatal consequences for patients, which is why clinicians often use drugs that suppress immune system function to suppress these reactions. This therapy has limitations or shortcomings, which can also reduce the anticancer effect of donor cells on cancer cells in patients. Therefore, researchers now need to understand how to reduce grafts without reducing the anticancer effect of transplanted cells. Anti-host reaction.
Cytokine responsible for attack
In this study, the researchers found that in the graft-versus pathology, the production of cytokines called GM-CSF has a decisive role. GM-CSF is produced by a special type of white blood cells. Help protect against infections in the body of healthy people. In the article, the researchers used a mouse model to study that these transplanted cells produced a large amount of GM-CSF factor during the graft-versus-host reaction. If the mouse body was injected with donor cells that could not produce GM-CSF. Then, the mice are immune to lethal reactions, so targeting this cytokine can produce a precise, specific immunosuppressive effect, which may be expected to block the graft-versus-host response. Tissue damage.
At first, researchers were worried that neutralizing GM-CSF factor would reduce the anticancer effect of donor cells. However, after in-depth research, they found that the actual situation may not be the case; the researcher Sonia Tugues said that the actual research results made us very Surprisingly, we previously thought that all types of immune responses are mediated by the same mechanism, and now we have found a way to separate the desired process from the unwanted process from the donor cell.
Transforming the results of mouse organisms into human clinical trials
The researchers then wanted to clarify whether the GM-CSF factor plays the same key role in the human body and in the mouse body. By analyzing the tissue from the patient's body in response to the graft-versus-host reaction, the researchers found that Thus, the levels of GM-CSF in these samples are higher, and when the patient's graft-versus-host response is stronger, the level of GM-CSF factor in the affected tissues will increase accordingly.
Researchers now hope to be able to conduct clinical trials to detect whether blocking the function of GM-CSF factor can inhibit graft-versus-host response in recipient patients after stem cell transplantation; researchers have now contacted a family that can develop blocking GM- Becher, a researcher at CSF monoclonal antibodies, said that if it can block the graft-versus-host response while retaining the anti-cancer effect, this process may successfully improve the patient's prognosis and bring smaller patients. Side effects, this therapeutic strategy may be expected to help improve the health of patients with a poor prognosis or risk of death.
Original source: Sonia Tugues1, Ana Amorim1, Sabine Spath, et al. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells, Science Translational Medicine 28 Nov 2018,Vol 10, Issue 469, eaat8410 DOI: 10.1126/scitranslmed.aat8410